Dapagliflozin constituted the majority of prescriptions (60%) followed by empagliflozin (40%). 69% were unclear why they were on SGLT2i and only 12% read the manufacturer's PIL. Understanding of adverse effects
When using the saxagliptin combination products saxagliptin/dapagliflozin or saxagliptin/dapagliflozin/metformin, avoid use with strong CYP3A4 inhibitors. Consider therapy modification Selpercatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Selpercatinib. Management: Avoid ...
Dapagliflozin Desipramine Desvenlafaxine Dexibuprofen Dexketoprofen Dextroamphetamine Dextromethorphan Diazoxide Dibenzepin Diclofenac Difenoxin Diflunisal Dihydrocodeine Diphenoxylate Dipyrone Dolasetron Domperidone Donepezil Doxepin Droperidol Droxicam Duloxetine Eletriptan Empagliflozin Enalapril Enalaprilat Eprosartan Ertuglif...